Related references
Note: Only part of the references are listed.
Article
Immunology
Elizabeth Robilotti et al.
Summary: A study of over 13000 healthcare personnel (HCP) showed that messenger RNA (mRNA) vaccine effectiveness (VE) against coronavirus disease 2019 (COVID-19) was 94% through initial 5 months of follow-up, with moderate VE reduction to 75% during subsequent Delta-dominant period. No hospitalizations occurred among vaccinated HCP throughout the study period.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Medicine, Research & Experimental
Matthew Zirui Tay et al.
Summary: The study found that the Delta variant of the SARS-CoV-2 virus can infect vaccinated individuals. Vaccine breakthrough cases showed lower memory B cell frequencies against the SARS-CoV-2 receptor-binding domain, but antibodies secreted by memory B cells retained neutralizing properties against the Delta variant. Inflammatory cytokines were lower in vaccine breakthrough infections compared to primary infections, highlighting the importance of vaccination in preventing inflammation.
EMBO MOLECULAR MEDICINE
(2022)
Article
Medicine, General & Internal
Seonju Yi et al.
Summary: This study investigates an outbreak of the SARS-CoV-2 Delta variant in a high vaccination rate adult day service center in South Korea, and estimates the secondary transmission prevention effect of the vaccine in household members. The results show a high infection rate in the center, even among fully vaccinated individuals, and transmission to unvaccinated or partially vaccinated household members. This highlights the importance of vaccinating close contacts of high-risk groups.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2022)
Article
Virology
Urvashi B. Singh et al.
Summary: This study analyzed the genomic profiles of breakthrough infections following vaccination with different vaccines, and found that variants of concern B.1.617.2 and B.1.1.7 were the predominant lineages causing a surge in cases in Delhi, India during April-May 2021.
JOURNAL OF MEDICAL VIROLOGY
(2022)
Article
Medicine, General & Internal
Scott A. Halperin et al.
Summary: The Ad5-nCoV vaccine showed a 57.5% efficacy against PCR-confirmed COVID-19 infection at least 28 days post-vaccination and demonstrated safety in healthy adults aged 18 years and older during the phase 3 trial.
Article
Virology
Kame A. Galan-Huerta et al.
Summary: This study investigated SARS-CoV-2 vaccine breakthrough infections in Monterrey, Mexico and found that the CanSino vaccine was most commonly administered. The Delta B.1.617.2 variant predominated in vaccinated ambulatory patients, while the AY.4 variant was detected in hospitalized patients. The Mu B.1.621 variant was found in a small percentage of vaccinated patients.
Article
Medicine, General & Internal
Jing Sun et al.
Summary: The study revealed that full vaccination was associated with reduced risk of COVID-19 breakthrough infection, regardless of the immune status of patients. Despite full vaccination, persons with immune dysfunction had substantially higher risk for COVID-19 breakthrough infection than those without such a condition. Continued use of nonpharmaceutical interventions (eg, mask wearing) and alternative vaccine strategies (eg, additional doses or immunogenicity testing) are recommended for persons with immune dysfunction after full vaccination.
JAMA INTERNAL MEDICINE
(2022)
Article
Public, Environmental & Occupational Health
Reem S. Almaghrabi et al.
Summary: Solid organ transplant recipients who are fully vaccinated may still be at risk of breakthrough infections from SARS-CoV-2 variants of concern, as shown in this case series. Some patients experienced severe pneumonia and required intensive care and ventilatory support. Younger patients had better outcomes.
JOURNAL OF INFECTION AND PUBLIC HEALTH
(2022)
Article
Microbiology
Venice Servellita et al.
Summary: A combined analysis of SARS-CoV-2 viral load and whole-genome sequences from COVID-19 patients reveals that vaccine breakthrough infections are more commonly associated with antibody-resistant SARS-CoV-2 variants than infections in unvaccinated individuals, and that symptomatic breakthrough infections may be as efficient in spreading COVID-19 as unvaccinated infections.
NATURE MICROBIOLOGY
(2022)
Article
Immunology
Lidewij W. Rumke et al.
Summary: Breakthrough infections of SARS-CoV-2 occurred in fully vaccinated individuals, showing regular variants and high viral loads despite normal immune responses. High-risk exposure settings indicate potential viral transmission even after full vaccination.
OPEN FORUM INFECTIOUS DISEASES
(2022)
Article
Immunology
Pratibha Kale et al.
Summary: This study investigated the clinical, humoral immune response, and genomic analysis of breakthrough infections in healthcare workers after receiving the ChAdOx1 nCoV-19/Covishield vaccine. The results showed that vaccinated individuals had a lower risk of infection and a stronger antibody response compared to unvaccinated individuals. The Delta variant was found to be predominant in the breakthrough infections.
Article
Medicine, General & Internal
Sumit Malhotra et al.
Summary: The study suggests that the BBV152 vaccine is associated with protection against symptomatic and asymptomatic reinfection in HCWs after complete vaccination, with the predominant circulating variant being B.1.617.2.
Article
Medicine, General & Internal
Elio Bignardi et al.
Summary: This article reports a clinical case resembling a breakthrough infection, which occurred at least 2 weeks after vaccination and was correlated with a positive result for the delta variant. The patient had a higher score of COVID-19 pneumonia on chest CT and died during hospitalization.
CLINICAL CASE REPORTS
(2022)
Letter
Infectious Diseases
Jeromie Wesley Vivian Thangaraj et al.
JOURNAL OF INFECTION
(2022)
Article
Immunology
Radhika Gharpure et al.
Summary: During July 2021, a multistate investigation was conducted after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.617.2 variant infections, including vaccine breakthrough infections, occurred following large public gatherings in Provincetown, Massachusetts, USA. The investigation revealed that large gatherings can have widespread effects on SARS-CoV-2 transmission, and even fully vaccinated individuals should take precautions to prevent transmission.
EMERGING INFECTIOUS DISEASES
(2022)
Article
Pathology
Randall J. Olsen et al.
Summary: This study reports the SARS-CoV-2 genome sequences of 12,476 patients diagnosed in the Houston Methodist health care system from January 1 to May 31, 2021. It highlights the rapid increase of the B.1.1.7 variant, causing a significant proportion of new cases in late May in Houston, TX, as well as the emergence of the B.1.617 variants in the metroplex.
AMERICAN JOURNAL OF PATHOLOGY
(2021)
Article
Multidisciplinary Sciences
Tyler N. Starr et al.
Summary: Research has found that mutations in the receptor binding domain (RBD) of SARS-CoV-2 may potentially escape the action of the REGN-COV2 cocktail, providing important information for interpreting mutations observed during viral surveillance.
Article
Immunology
Lotem Goldberg et al.
Summary: This report presents the first evidence of nosocomial infections of SARS-CoV-2 despite the use of surgical masks and physical distancing, suggesting the possibility of airborne transmission of the virus.
OPEN FORUM INFECTIOUS DISEASES
(2021)
Article
Biochemistry & Molecular Biology
Qianqian Li et al.
Summary: The 501Y.V2 variants of SARS-CoV-2 with multiple mutations are rapidly spreading from South Africa to other countries, showing reduced susceptibility to neutralizing antibodies and potential compromise of monoclonal antibodies and vaccines. Enhanced infectivity in murine ACE2-overexpressing cells suggests the possibility of transmission to mice.
Article
Biochemistry & Molecular Biology
Daming Zhou et al.
Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.
Article
Microbiology
Zhuoming Liu et al.
Summary: The study found that antibodies targeting the SARS-CoV-2 spike protein have escape mutations, different monoclonal antibodies have unique resistance profiles, some mutants are resistant to multiple antibodies while some variants can escape neutralization by convalescent sera. Comparing antibody-mediated mutations with circulating SARS-CoV-2 sequences revealed substitutions that may weaken neutralizing immune responses in some individuals, warranting further investigation.
CELL HOST & MICROBE
(2021)
Article
Biochemistry & Molecular Biology
Matan Levine-Tiefenbrun et al.
Summary: The study found that the effectiveness of the BNT162b2 vaccine in reducing viral loads of breakthrough infections decreases over time. However, this reduction in viral load can be restored by receiving a third vaccine dose.
Article
Biochemistry & Molecular Biology
Rachna T. Shroff et al.
Summary: Cancer patients showed diminished immune responses to the BNT162b2 mRNA vaccine compared to the control group, but a third dose of the vaccine was found to be safe and significantly improved humoral immunity against SARS-CoV-2.
Article
Multidisciplinary Sciences
Zijun Wang et al.
Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.
Article
Biochemistry & Molecular Biology
Rita E. Chen et al.
Summary: The study analyzed antibody neutralization activity against a panel of authentic isolates and chimeric SARS-CoV-2 variants, showing significantly reduced neutralizing activity against the B.1.351 variant first identified in South Africa. Antibodies targeting the receptor-binding domain and N-terminal domain, monoclonal antibodies, convalescent sera, and mRNA vaccine-induced immune sera exhibited decreased inhibitory activity against viruses with an E484K spike mutation, suggesting a need for updated monoclonal antibodies or vaccine adjustments to prevent loss of protection against emerging variants.
Article
Virology
William M. de Souza et al.
Summary: The study found that the B.1.1.7 VOC variant can infect vaccinated individuals, especially those who have received only one dose of the vaccine. Although the vaccines can reduce the risk of severe disease and death caused by this variant, some individuals still get infected.
Article
Multidisciplinary Sciences
Francesca Rovida et al.
Summary: A study of healthcare workers vaccinated with BNT162b2 vaccine showed an 83% protection rate against SARS-CoV-2 infection in the overall population and 93% in previously infected individuals. Evidence of virus transmission was low, with breakthrough infections mostly asymptomatic or mild, supporting the real-world effectiveness of the vaccine.
NATURE COMMUNICATIONS
(2021)
Article
Medicine, General & Internal
Mie Agermose Gram et al.
Summary: A Danish nationwide population-based cohort study found that combining the ChAdOx1 vaccine with an mRNA vaccine resulted in 88% protection against SARS-CoV-2 infection. There were no COVID-19-related hospitalizations or deaths among individuals vaccinated with the combined vaccine schedule during the study period.
Article
Microbiology
Pengfei Wang et al.
Summary: The emerging Brazilian variant P.1 shows increased resistance to antibody neutralization, posing a threat to current antibody therapies, but has less impact on the effectiveness of protective vaccines.
CELL HOST & MICROBE
(2021)
Article
Medicine, General & Internal
Katherine R. W. Emary et al.
Summary: A post-hoc analysis was conducted on the efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.1.7 variant of SARS-CoV-2 in the UK. The vaccine showed reduced neutralisation activity against the B.1.1.7 variant in vitro, but still demonstrated efficacy against the B.1.1.7 variant of the virus.
Article
Multidisciplinary Sciences
Sandile Cele et al.
Summary: The study compared the neutralization of non-VOC and 501Y.V2 VOC variants using plasma from COVID-19 patients in South Africa. It found that plasma from individuals infected during the first wave effectively neutralized the first-wave virus variant, while plasma from those infected in the second wave effectively neutralized the 501Y.V2 variant.
Letter
Medicine, General & Internal
Salim S. Abdool Karim et al.
Summary: The emergence of SARS-CoV-2 variants, including B.1.1.7 (VOC-202012/01), 501Y.V2 (B.1.351), and P.1 (B.1.1.28.1), has raised concerns about worsening Covid-19 and potential escape from vaccine-induced immunity.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Ezgi Hacisuleyman et al.
Summary: Despite evidence of vaccine efficacy, two fully vaccinated individuals developed mild symptoms of Covid-19 and were infected with variants of SARS-CoV-2. Sequencing of the virus isolates revealed novel mutations, highlighting the potential risk of illness post-vaccination and subsequent infection with variant virus. Efforts to prevent, diagnose, and characterize variants in vaccinated individuals are crucial.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Nicole Doria-Rose et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Jamie Lopez Bernal et al.
Summary: This study estimated the real-world effectiveness of Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed COVID-19 symptoms, hospital admissions, and deaths. The vaccines showed significant reduction in symptomatic COVID-19 among older adults and further protection against severe disease. Both vaccines demonstrated similar effects and protection was maintained for over 6 weeks.
BMJ-BRITISH MEDICAL JOURNAL
(2021)
Article
Microbiology
Marco Fabiani et al.
Summary: The novel SARS-CoV-2 and COVID-19 are spreading worldwide, with multiple variants of concern impacting vaccine efficacy and treatments. An 83-year-old man was infected with the P.1 variant after receiving two doses of the BNT162b2 mRNA COVID-19 vaccine.
Article
Medicine, General & Internal
Matthew J. Page et al.
SYSTEMATIC REVIEWS
(2021)
Article
Surgery
Nathalie Chavarot et al.
Summary: Poor responses to mRNA COVID-19 vaccine were observed in kidney transplant recipients treated with belatacept, especially in those without prior COVID-19 history. However, patients with a history of COVID-19 developed a strong antibody response with high titers after vaccination. Further strategies are needed to improve protection in this population.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Editorial Material
Surgery
Richard A. Teran et al.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Article
Surgery
Tina Schmidt et al.
Summary: This study found that solid organ transplant recipients had lower levels of SARS-CoV-2-specific antibodies and T cells compared to controls after homologous or heterologous vaccination. However, heterologous vaccination showed promise in improving immune responses in transplant recipients, with higher induction of antibodies and CD4 T cells.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Article
Surgery
Victoria G. Hall et al.
Summary: Solid organ transplant recipients are at high risk of severe COVID-19. A study on the immunogenicity of mRNA-1273 vaccine in this population showed that a subset of patients developed neutralizing antibodies and CD4+ T cell responses, emphasizing the importance of vaccination in this patient population.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Article
Microbiology
Chihiro Motozono et al.
Summary: Research has shown that certain mutations in SARS-CoV-2 variants can escape HLA-restricted cellular immunity, increase affinity for host cells, promote viral replication, and potentially affect the evolution of viral phenotypes.
CELL HOST & MICROBE
(2021)
Article
Infectious Diseases
Inge Kroidl et al.
Summary: In February 2021, a breakthrough infection of the SARS-CoV-2 B.1.351 variant occurred in a fully Comirnaty vaccinated healthcare worker, which was then transmitted to their unvaccinated spouse. Sequencing revealed an identical virus in both spouses, with all nine single nucleotide polymorphisms typical for B.1.351. To date, no transmission of any variant of SARS-CoV-2 from a fully vaccinated person has been documented.
Article
Immunology
Aurelien Sokal et al.
Summary: This study examined the MBC responses in recovered and naive individuals after mRNA vaccination against SARS-CoV-2, finding that the MBC pool in recovered individuals expanded selectively, matured further, and had potent neutralizers against VOCs. Naive individuals displayed weaker neutralizing serum responses, but a significant portion of their RBD-specific MBCs showed high affinity to multiple VOCs, suggesting potential efficient response to VOCs in naive vaccinees.
Article
Infectious Diseases
Bradley A. Connor et al.
Summary: Two cases of Delta variant vaccine breakthrough infections were reported, involving a father and son living separately. The 63-year-old father required hospitalization for severe symptoms, but his condition improved within 24 hours after receiving monoclonal antibody therapy despite having high levels of anti-spike IgG in his serum.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Letter
Infectious Diseases
J. Beena Philomina et al.
JOURNAL OF INFECTION
(2021)
Letter
Medicine, General & Internal
Inge K. Holden et al.
Summary: It is uncertain if a two-dose regimen of a Covid-19 vaccine is effective in eliciting an immune response in solid organ transplant (SOT) recipients. Only 35% of SOT recipients were able to mount a positive IgG immune response 6 weeks after the second dose of vaccine, indicating the need for continued personal protective measures. Future studies should focus on examining the cellular immune response in patients with compromised antibody response to Covid-19 vaccination.
JOURNAL OF INTERNAL MEDICINE
(2021)
Editorial Material
Public, Environmental & Occupational Health
Ying Liu et al.
Summary: The Delta variant is rapidly replacing other strains of SARS-CoV-2, with a higher R-0 value of 5.08 compared to the ancestral strain's 2.79. Increasing vaccine coverage and strengthening public health measures are now more urgent than ever to control the spread of the virus.
JOURNAL OF TRAVEL MEDICINE
(2021)
Letter
Medicine, General & Internal
Dan H. Barouch et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Medicine, General & Internal
Nassim Kamar et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
M. P. O'Brien et al.
Summary: The study indicates that subcutaneous REGEN-COV can effectively prevent severe Covid-19 and reduce the duration of symptoms in individuals at high risk for infection due to household exposure to confirmed SARS-CoV-2 cases.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Moriah Bergwerk et al.
Summary: Among fully vaccinated health care workers, breakthrough infections with SARS-CoV-2 were correlated with neutralizing antibody titers during the peri-infection period. Most breakthrough infections were mild or asymptomatic, although persistent symptoms did occur.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Philip R. Krause et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Virology
Cassia F. Estofolete et al.
Summary: The development of effective vaccines against COVID-19 has helped in reducing the transmission of the virus, but the emergence of variants poses challenges. Breakthrough infections after vaccination highlight the importance of continued vigilance and efforts to prevent and diagnose infections among vaccinated individuals.
Article
Virology
Xufang Deng et al.
Summary: Studying the role of SARS-CoV-2 viral variants in causing severe disease, evading vaccine-induced immunity, and infecting vulnerable individuals is crucial for controlling the COVID-19 pandemic. Findings show that breakthrough infections in vaccinated individuals may have high viral loads, with immunosuppressed individuals being more susceptible to hospitalization after infection.
Article
Virology
Nivedita Gupta et al.
Summary: The study revealed that the majority of breakthrough COVID-19 cases in India were infected with the Delta variant, with only 9.8% requiring hospitalization and a fatality rate of 0.4%. This suggests that vaccination significantly reduces the risk of hospitalization and mortality.
Article
Multidisciplinary Sciences
Allison J. Greaney et al.
Summary: The study found that although the human immune system can produce antibodies that target diverse RBD epitopes, in practice, the polyclonal response to infection tends to be skewed towards a single class of antibodies targeting an epitope that is already undergoing rapid evolution.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Matthias Becker et al.
Summary: This study characterizes the antibody response from vaccinated, infected, and uninfected individuals against emerging variants of concern of SARS-CoV-2, indicating reduced neutralization of a South African isolate. High IgG titers in the saliva of vaccinees suggest reduced transmission potential.
NATURE COMMUNICATIONS
(2021)
Article
Public, Environmental & Occupational Health
Meseret Birhane et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Review
Infectious Diseases
Maria Teresa Mascellino et al.
Summary: This review discusses the principal vaccines developed against SARS-CoV-2 during the Covid-19 pandemic, evaluating their mechanisms of action, efficacy, safety, and storage temperature. It also delves into dosing issues, vaccination strategies, monoclonal antibodies, and the challenges posed by virus variants. The review highlights the varying efficacy of different vaccines and emphasizes the importance of vaccination strategies based on age groups to achieve herd immunity quickly.
INFECTION AND DRUG RESISTANCE
(2021)
Article
Immunology
Yushi Nomura et al.
Summary: This study aimed to evaluate antibody titres 3 months after the second dose of the BNT162b2 COVID-19 vaccine in Japan and found that age and smoking were the most significant factors affecting antibody titres. Particularly, current smoking status was associated with lower antibody titres, suggesting smoking cessation before vaccination may improve vaccine efficacy.
Article
Medicine, General & Internal
Bianca Schulte et al.
Summary: This case demonstrates the possibility of SARS-CoV-2 infection in a vaccinated individual, with high viral replication in the presence of strong antibody responses. The virus was able to transmit to others, as shown by infections in household members, emphasizing the importance of protective measures even among vaccinated individuals.
FRONTIERS IN MEDICINE
(2021)
Article
Medicine, General & Internal
Jayanthi Shastri et al.
Summary: The study found that despite post-vaccination immunity and immunity acquired through past infection, breakthrough infections caused by Variants of Concern can still occur in COVID-19 cases. A patient in the study experienced breakthrough infections with the Alpha variant and the Delta variant, the latter resulting in severe illness even after boosting. The source of infection was established through clinical data and genetic sequencing.
FRONTIERS IN MEDICINE
(2021)
Letter
Medicine, General & Internal
Mark P. Lythgoe et al.
Summary: This qualitative improvement study examines COVID-19 vaccine approvals by medicine regulatory agencies in the US, EU, and Canada, comparing regulatory review times and analyzing clinical evidence supporting authorization.
Article
Medicine, General & Internal
Shepherd R. Singer et al.
Summary: In Israel, two doses of BNT162b2 were found to be 72% effective against confirmed and probable Beta infections, and 100% effective against symptomatic confirmed or probable Beta infections. However, there was no evidence of protection in partially-vaccinated contacts.
Article
Oncology
Annika Fendler et al.
Summary: Patients with cancer have higher morbidity and mortality when infected with COVID-19. The CAPTURE study found that while most patients had immune responses against the original SARS-CoV-2, neutralizing antibody titers against variants were significantly reduced, with some patients experiencing a decrease in antibody levels. However, neutralizing antibody titers remained stable for some patients.
Letter
Immunology
Andreina Baj et al.
Summary: The Delta variant of concern, specifically the B.1.617.2 sublineage with the E484K mutation, caused a case cluster in Italy. This mutation is believed to impact immune response and vaccine efficacy, highlighting the importance of monitoring its spread.
EMERGING INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Nguyen Van Vinh Chau et al.
Summary: The study found breakthrough Delta variant infections among healthcare workers vaccinated with Oxford-AstraZeneca in Vietnam, occurring 7-8 weeks after the second dose. Most cases were asymptomatic or mildly symptomatic and all recovered. High viral loads, prolonged PCR positivity, and low levels of vaccine-induced neutralizing antibodies were associated with these breakthrough infections.
Article
Health Care Sciences & Services
Peter Nordstrom et al.
Summary: The study suggests that heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and mRNA vaccines is an effective alternative to increase population immunity against Covid-19, with higher effectiveness compared to homologous vaccination. These findings could have significant implications for vaccination strategies and logistics in the battle against the Covid-19 pandemic.
LANCET REGIONAL HEALTH-EUROPE
(2021)
Article
Immunology
Nicolas Vignier et al.
Summary: An outbreak of severe acute respiratory syndrome coronavirus 2 caused by the Gamma variant infected 55% of employees at a gold mine in French Guiana, with 87% showing symptoms but no severe cases. Among fully vaccinated miners, the attack rate was 60%, while it was 75% among unvaccinated miners without a history of infection.
EMERGING INFECTIOUS DISEASES
(2021)
Article
Immunology
Pinkus Tober-Lau et al.
Summary: One week after the second vaccinations, an outbreak of B.1.1.7 lineage COVID-19 infections occurred in a long-term care facility in Berlin, Germany, affecting 16/20 vaccinated and 4/4 unvaccinated residents. Despite high viral loads, vaccinated residents experienced mild symptoms and faster time to negative test results.
EMERGING INFECTIOUS DISEASES
(2021)
Article
Immunology
Alberto Zani et al.
Summary: The study demonstrates that antibodies generated by the BNT162b2 vaccine can efficiently neutralize authentic viruses belonging to various SARS-CoV-2 lineages. Neutralization was highest for B.1.1.7 and B.1.525 lineages, while lower for B.1.351 and P.1 lineages compared to the B.1 lineage. The findings suggest that the BNT162b2 vaccine offers protection against the prevailing variants of SARS-CoV-2.
EMERGING MICROBES & INFECTIONS
(2021)
Letter
Infectious Diseases
Sonia Jangra et al.
Article
Cell Biology
Tyler N. Starr et al.
Summary: The study mapped mutations to the SARS-CoV-2 spike receptor-binding domain that escape binding by certain monoclonal antibodies. These mutations are concentrated in specific lineages of SARS-CoV-2. The authors suggest diversifying the epitopes targeted by antibodies and antibody cocktails to make them more resilient to SARS-CoV-2 antigenic evolution.
CELL REPORTS MEDICINE
(2021)
Article
Multidisciplinary Sciences
Fan Wu et al.
Review
Medicine, General & Internal
Roger Chou et al.
ANNALS OF INTERNAL MEDICINE
(2020)
Article
Biochemistry & Molecular Biology
Alba Grifoni et al.
Article
Biochemistry & Molecular Biology
Tyler N. Starr et al.
Review
Immunology
Luis F. Garcia
FRONTIERS IN IMMUNOLOGY
(2020)
Review
Chemistry, Multidisciplinary
Xingwu Zhou et al.
Article
Biochemistry & Molecular Biology
Luca Piccoli et al.
Article
Biochemistry & Molecular Biology
Arthur W. D. Edridge et al.
Article
Infectious Diseases
Brechje de Gier et al.
Article
Multidisciplinary Sciences
Lizhou Zhang et al.
NATURE COMMUNICATIONS
(2020)
Article
Multidisciplinary Sciences
Yixuan J. Hou et al.
